文献速递肝病

回肠胆汁酸转运抑制剂治疗胆汁淤积性肝病综述

Review Article: Ileal Bile Acid Transport (IBAT) Inhibitors as an Emerging Treatment for Cholestatic Liver Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2026-04-09

本文综述回肠胆汁酸转运(IBAT)抑制剂在胆汁淤积性肝病中的应用。儿童ALGS和PFIC的2/3期试验显示odevixibat和maralixibat显著减轻瘙痒并降低血清胆汁酸;PBC的3期试验显示linerixibat改善瘙痒。PBC和PSC常见轻中度胃肠道副作用,长期影响尚待研究。

要点

  • IBAT抑制剂是首个靶向肠肝胆汁酸循环的上游药物。
  • odevixibat和maralixibat在儿童ALGS和PFIC中减轻瘙痒并降低胆汁酸。
  • linerixibat在PBC 3期试验中改善瘙痒;PSC角色未明。

核心结论

  • IBAT抑制剂是首个靶向肠肝胆汁酸再循环的上游药物,在ALGS和PFIC中可有效减轻瘙痒。
  • IBAT抑制剂在PBC和PSC中的作用尚不明确,需长期研究评估对纤维化、肝癌风险和移植生存的影响。

研究设计与样本

  • 叙述性综述,检索PubMed 2000年1月至2025年8月文献,总结IBAT抑制剂在ALGS、PFIC、PBC和PSC中的机制、疗效和安全性。

主要发现

  • 儿童ALGS和PFIC的2期和3期试验中,odevixibat和maralixibat显著减轻瘙痒并降低血清胆汁酸浓度。
  • 事后分析中,应答者较历史对照队列显示无事件生存和无移植生存改善。
  • PBC的3期试验中,linerixibat较安慰剂改善瘙痒。
  • IBAT抑制常见轻中度胃肠道副作用,最常为腹泻和腹部不适,尤其在PBC和PSC中。

临床怎么用

  • IBAT抑制剂可用于ALGS和PFIC患儿减轻瘙痒,需关注腹泻和腹部不适等胃肠道副作用。

局限性

  • PBC和PSC中的作用尚未明确,需长期研究评估对纤维化进展、肝细胞癌风险和移植生存的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cholestatic liver diseases such as Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) cause significant morbidity and mortality. Chronic pruritus is common, debilitating, and impairs health-related quality of life. Recently, pharmacological inhibition of the ileal bile acid transporter (IBAT) has emerged as a therapeutic target. AIMS: To review the current landscape of IBAT inhibitors, summarise emerging clinical data, discuss their role in the treatment of cholestatic liver diseases and future directions for their development and use. METHODS: This narrative review summarises current data on IBAT inhibitors, exploring their mechanisms, efficacy, and safety across ALGS, PFIC, PBC and PSC. References were identified through searches of PubMed from January 2000 to August 2025. RESULTS: In phase 2 and 3 trials involving paediatric patients with ALGS and PFIC, IBAT inhibitors (odevixibat and maralixibat) significantly reduced pruritus and serum bile acid concentrations. In post hoc analysis, responders demonstrated improved event-free and transplant-free survival compared to historic control cohorts. The phase 3 trial of linerixibat in PBC demonstrated an improvement in pruritus compared to placebo. Mild to moderate gastrointestinal side effects, most commonly diarrhoea and abdominal discomfort, are common with IBAT inhibition, particularly in PBC and PSC. CONCLUSIONS: IBAT inhibitors represent the first upstream pharmacotherapy targeting enterohepatic bile acid recirculation and are effective at reducing pruritus in ALGS and PFIC. Their role in PBC and PSC is promising yet undefined. Long-term studies are needed to assess effects on fibrosis progression, hepatocellular carcinoma risk and transplant-free survival.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Peverelle M, Campbell SMA, Peverelle J, et al. Review Article: Ileal Bile Acid Transport (IBAT) Inhibitors as an Emerging Treatment for Cholestatic Liver Disease. Aliment Pharmacol Ther. 2026. PMID: 41953994. doi:10.1111/apt.70666

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。